New Review of Optimal Dose and Cost-effectiveness of Ranibizumab Treatment of Diabetic Macular Oedema

Tuesday, February 7, 2017 Diabetes News
Email Print This Page Comment

LONDON, February 7, 2017 /PRNewswire/ --

Jean-François Korobelnik, European Ophthalmic Review, 2016;10(2):125-31

DOI: https://doi.org/10.17925/EOR.2016.10.02.125

     (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO )

Published recently in European Ophthalmic Review, the peer-reviewed journal from touchOPHTHALMOLOGY,

Korobelnik discusses ranibizumab (Lucentis®) a key treatment for diabetic macular oedema (DMO) that is, approved at differing doses: 0.5 mg/month in Europe and 0.3 mg/month in the US. The relative efficacy and safety of these doses, however, is a controversial issue. A wide ranging literature search was conducted to examine the evidence supporting these doses. The searches identified only four studies that evaluated the 0.3 mg ranibizumab dose, in which best-corrected visual acuity (BCVA) improvements ranged from +5.7 to +12.8 letters during treatment. The searches also identified 12 key studies that evaluated the 0.5 mg dose of ranibizumab, in which BCVA improvement ranged from +6.1 to +10.3 letters. The pivotal RIDE and RISE studies (n=382 and 377) were the only direct head-to-head comparisons of the 0.3 mg and 0.5 mg ranibizumab doses and placebo. A pooled analysis of these studies showed that improvements in BCVA were numerically higher for the 0.3 mg-treated groups than for the 0.5 mg-treated groups at 24 and 36 months. Patients who were initially treated with sham injections and switched to ranibizumab did not match the improvements in those treated from the start. There was also little difference in central retinal thickness reduction between the two doses (261.8 and 261.2 ?m versus 266.7 and 269.1 ?m). Ranibizumab was well tolerated, adverse events occurred at similar frequencies in all groups, with a slightly greater incidence of stroke for the 0.5 mg dose. Analysis of RIDE and RISE also showed that ranibizumab is cost-effective. Overall, the data indicate that the 0.3 mg dose of ranibizumab is generally as effective as the 0.5 mg dose in DMO treatment.

The full peer-reviewed, open-access article is available here:

https://doi.org/10.17925/EOR.2016.10.02.125

Disclosure: Jean-Francois Korobelnik has been a consultant for Alcon, Alimera, Allergan, Bayer, Horus, Novartis, Roche, Théa and Zeiss.

Note to the Editor

touchOPHTHALMOLOGY (a division of Touch Medical Media) publishes the European Ophthalmic Review, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of ophthalmology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.

http://www.touchOPHTHALMOLOGY.com

For inquires please contact:

Nicola Cartridge - Managing Editor

+44(0)207-193-3186

editor@touchmedicalmedia.com

Providing practical opinion to support best practice for busy healthcare professionals.

SOURCE touchOPHTHALMOLOGY



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook